Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD

Blood (2016) 128 (22): 2111.

https://doi.org/10.1182/blood.V128.22.2111.2111

Published: 2016

Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Blood (2015) 126 (23): 727.

https://doi.org/10.1182/blood.V126.23.727.727

Published: 2015

Journal Articles

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta, PhD, Michael J Hanley, PhD, R. Donald Harvey, PharmD, Ashraf Z Badros, MD, Brea C. Lipe, MD, Vishal Kukreti, Jesus G. Berdeja, MD, Huyuan Yang, PhD, Ai-Min Hui, MD PhD, Xiaoquan Zhang, MD PhD, Karthik Venkatakrishnan, PhD, Ajai Chari, MD

Blood (2015) 126 (23): 4227.

https://doi.org/10.1182/blood.V126.23.4227.4227

Published: 2015

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Zonder A Jeffrey, MD, Vishal Kukreti, MD FRCPC, Stefan O Schoenland, MD, Arnaud Jaccard, MD, Angela Dispenzieri, MD, Adam D. Cohen, MD, Deborah Berg, RN, MSN, Zheng Yuan, PhD, Ai-Min Hui, MD PhD, Palladini Giovanni, MD PhD, Raymond L. Comenzo, MD

Blood (2014) 124 (21): 3450.

https://doi.org/10.1182/blood.V124.21.3450.3450

Published: 2014

Journal Articles

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Jacob P. Laubach, MD, Mehdi Hamadani, MD, A. Keith Stewart, MD, Parameswaran N. Hari, MD, Vivek Roy, MD, Robert Vescio, MD, Jonathan L. Kaufman, MD, Deborah Berg, RN, MSN, Eileen Liao, PhD, Ai-Min Hui, MD PhD, S. Vincent Rajkumar, MD, Paul G. Richardson

Blood (2014) 124 (21): 82.

https://doi.org/10.1182/blood.V124.21.82.82

Published: 2014

Journal Articles

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Sarit Assouline, Julie E. Chang, MD, Bruce D. Cheson, MD, Robert Rifkin, MD, Solomon Hamburg, MD, PhD, Ruben Reyes, MD, Ai-Min Hui, MD, PhD, Jiang Yu, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Yaping Shou, Peter Martin, MD

Blood (2012) 120 (21): 3646.

https://doi.org/10.1182/blood.V120.21.3646.3646

Published: 2012

Journal Articles

MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

Giampaolo Merlini, Vaishali Sanchorawala, Jeffrey A. Zonder, MD, Vishal Kukreti, MD, Stefan O Schonland, MD, Arnaud Jaccard, Angela Dispenzieri, MD, Adam D. Cohen, Deborah Berg, RN, MSN, Guohui Liu, PhD, Alessandra Di Bacco, PhD, Neeraj Gupta, PhD, Ai-Min Hui, MD, PhD, Giovanni Palladini, Raymond L. Comenzo, MD

Blood (2012) 120 (21): 731.

https://doi.org/10.1182/blood.V120.21.731.731

Published: 2012

NARROW

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only